For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Kalobios Pharmaceuticals, Inc.

USPTO Granted Patents = 19

CIPO Patents = 1

EPO Patents = 7

Trademarks = 1

Forward Citations = 65

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Christopher Robert Bebbington (16 out of 44 patents)

Geoffrey T Yarranton (16 out of 28 patents)

Kenneth Luehrsen (8 out of 10 patents)

4. Mark Baer (4 out of 7 patents)

5. Varghese Palath (4 out of 4 patents)

6. David Martinez (3 out of 3 patents)

7. Jeng-Horng Her (3 out of 15 patents)

8. Robert F Balint (3 out of 6 patents)

9. Christina Yi (2 out of 2 patents)

10. Peter Flynn (1 out of 10 patents)

11. Nenad Tomasevic (1 out of 10 patents)

12. Bo Yu (1 out of 17 patents)

13. Martin Lackmann (1 out of 4 patents)

14. Jason Williams (1 out of 2 patents)

15. Andrew Ewart Scott (1 out of 11 patents)

19 patents: Sort by Forward Citations

1. 9290571 - Antibodies to EphA3 (2016-03-22),

2. 9127046 - Secretion of antibodies without signal peptides from bacteria (2015-09-08),

3. 9109032 - Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow (2015-08-18),

4. 9045539 - Anti-EMR1 antibodies (2015-06-02),

5. 9017674 - Antibodies to granulocyte-macrophage colony-stimulating factor (2015-04-28),

6. 8877191 - [object Object] (2014-11-04),

7. 8834870 - Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 (2014-09-16),

8. 8664365 - Antibodies to EphA3 (2014-03-04),

9. 8642039 - [object Object] (2014-02-04),

10. 8637016 - EphA3 antibodies for the treatment of solid tumors (2014-01-28),

11. 8398972 - Methods of treating dementia using a GM-CSF antagonist (2013-03-19),

12. 8354251 - Transactivation system for mammalian cells (2013-01-15),

13. 8211648 - Secretion of antibodies without signal peptides from bacteria (2012-07-03),

14. 8168183 - Antibodies to granulocyte-macrophage colony-stimulating factor (2012-05-01),

15. 8075885 - Methods of treating heart failure using an anti-GM-CSF antibody (2011-12-13),

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative monoclonal antibody therapeutics for the treatment of severe respiratory diseases, cancer, and rare diseases. Their innovative approach and expertise in antibody technologies have led to the development of promising drug candidates. KaloBios is committed to improving patients' lives through the advancement of novel and effective treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

19 Patents

#63 in South San Francisco, CA

#3,975 in California

#16,627 in US

#31,713 in the World

South San Francisco, CA, United States of America

Kalobios Pharmaceuticals, Inc.

Forward Citations = 65

18 inventors:

Christopher Robert Bebbington (16 out of 44 patents)

Geoffrey T Yarranton (16 out of 28 patents)

Kenneth Luehrsen (8 out of 10 patents)

4. Mark Baer (4 out of 7 patents)

5. Varghese Palath (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…